Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone Refractory Prostate Cancer × cabozantinib × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡